尔康制药实控人帅放文拟套现1.5亿 此前已套现10.5亿

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, due to personal funding needs [1][4]. Group 1: Shareholder Information - Shuai Fangwen currently holds 853,574,906 shares, which is 41.38% of the total share capital [1]. - The planned reduction will occur within three months from October 29, 2025, to January 28, 2026, through centralized bidding or block trading [1]. - After the reduction, Shuai Fangwen will remain the controlling shareholder, and the company's control will not change [4]. Group 2: Financial Implications - Based on the closing price of 3.49 yuan on September 29, 2023, the planned cash-out from this reduction is approximately 147 million yuan [2]. - Since 2017, Shuai Fangwen has cumulatively reduced his holdings by 88,769,100 shares, amounting to approximately 1.05 billion yuan in cash [5]. - Including the current planned reduction, the total cash-out from share reductions will reach approximately 1.197 billion yuan [5].